Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2010

View Archived Issues

TLR7 agonist AZD-8848 efficacious in rhinitis and asthma models

Improvements in depression and related disability seen with levomilnacipran

Epodure biopump sustains elevated Hb levels for 1 year

Serum SDF-1-alpha levels correlate with long-term prognosis of stroke

Fingolimod shows promise in mouse model of cerebral ischemia

Pharmacokinetic data disclosed on cinaciguat in hepatic and renal impairment

REDUCE and CombAT trial data presented on dutasteride in prostate cancer

AstraZeneca claims new DNA topoisomerase 4 inhibitors

New beta-secretase inhibitors described by AstraZeneca

Roche presents new tachykinin NK3 receptor antagonists

Banyu and Merck & Co. disclose new DGAT-1 inhibitors

StronBone bone graft substitute shows efficacy in vivo

FDA grants fast track status to AS-1413 for secondary AML

Kyowa Hakko Kirin and BLS enter licensing agreement for istradefylline

FDA to review Eisai's NDA for AcipHex ER 50-mg tablets

Phase III RADIANT-3 trial of everolimus meets primary endpoint

FDA extends review period for Abstral

Johns Hopkins receives MSCRF grant to study Q-Cells in demyelinating disease

Galiximab shows minimal activity in relapsed Hodgkin's lymphoma

Verona Pharma provides company update at annual general meeting

Ablynx and reMYND settle dispute relating to Nanobodies agreement

Phase IIb trial of PEG-Interferon lambda initiated in hepatitis C

Encouraging phase Ib/II data reported on AVI-4658 in DMD

PregLem reports phase III data on Esmya in uterine fibroids

FDA issues updated recommendations for LABAs

Grifols to begin clinical trial of new Alzheimer's disease therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...